Zwimpfer Tibor A, Bilir Esra, Gasimli Khayal, Cokan Andrej, Bizzarri Nicolò, Razumova Zoia, Kacperczyk-Bartnik Joanna, Nikolova Tanja, Pletnev Andrei, Kahramanoglu Ilker, Shushkevich Alexander, Strojna Aleksandra, Theofanakis Charalampos, Cicakova Tereza, Vetter Marcus, Montavon Céline, Morgan Gilberto, Heinzelmann-Schwarz Viola
Peter MacCallum Cancer Center, East Melbourne, VIC 3002, Australia.
Gynecological Cancer Center, University Hospital Basel, 4031 Basel, Switzerland.
Cancers (Basel). 2024 Mar 14;16(6):1155. doi: 10.3390/cancers16061155.
Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% ( = 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1-2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3-4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted.
铂类和紫杉烷类化疗与过敏反应（HSR）风险相关，这可能需要改用疗效较差的治疗方法。对铂类和紫杉烷类HSR进行脱敏可用于按照标准方案完成化疗。因此，我们旨在调查妇科癌症患者对铂类和/或紫杉烷类化疗HSR的当前管理情况。我们对妇科肿瘤学家和医学肿瘤学家进行了一项包含33个问题的在线横断面调查。共有144名受访者完成了调查，133名受访者纳入最终分析。大多数参与者是妇科肿瘤学家（43.6%）和医学肿瘤学家（33.8%），77.4%（n = 103）参与化疗治疗。超过73%的参与者每年经历超过5次铂类和紫杉烷类HSR。对于1 - 2级铂类和紫杉烷类HSR，分别有84.8%和92.5%的情况使用了预处理和重新尝试铂类或紫杉烷类化疗。相比之下，对于3 - 4级铂类和紫杉烷类HSR，分别有49.4%和41.8%的情况使用了脱敏治疗。大多数参与者强烈强调需要规范妇科癌症中铂类和紫杉烷类HSR的管理。我们的研究表明，妇科癌症中的HSR很常见，但管理方式不一，脱敏治疗的使用率较低。此外，突出了对妇科癌症中铂类和紫杉烷类诱导的HSR管理指南的需求。
